Clinical Trial Update: Bortezomib in Treating Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating bortezomib in patients with myelodysplastic syndromes has completed, with results posted in May 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: University of Rochester | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2016-05-09